Evidence map›Paper›PMID 36030248›Full record

ArticleCell death & disease2022

CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis.

Kui Luo, Aiqun Liu, Hao Wu, Qiang Liu, Jin Dai, Yu Liu, Zhifei Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kui Luo *Department of Neurosurgery, The Third Xiangya Hospital, Central South University, 410013, Changsha, Hunan, China.
Aiqun Liu *Department of Neurology, School of Clinical Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University, No.19 Nonglinxia Road, Guangzhou, Guangdong, People's Republic of China.
Hao WuDepartment of Neurosurgery, The Third Xiangya Hospital, Central South University, 410013, Changsha, Hunan, China.
Qiang LiuDepartment of Neurosurgery, The Third Xiangya Hospital, Central South University, 410013, Changsha, Hunan, China.
Jin DaiDepartment of Neurosurgery, The Third Xiangya Hospital, Central South University, 410013, Changsha, Hunan, China.
Yu LiuDepartment of Neurosurgery, The Third Xiangya Hospital, Central South University, 410013, Changsha, Hunan, China.
Zhifei WangDepartment of Neurosurgery, The Third Xiangya Hospital, Central South University, 410013, Changsha, Hunan, China. doctorwangzhifei@163.com.ORCID 0000-0002-3197-4380
Central South University · CNFirst Affiliated Hospital of Guangdong Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNAs (circRNAs) are a kind of noncoding RNAs that have different biological functions. CircRNAs play very important parts in the progression of cancers. Nevertheless, the exact mechanism and function of many circRNAs in glioma are not clear. In our study, circKIF4A was identified as a remarkably upregulated circRNA expressed in glioma tissues and cell lines. We performed loss-off function and gain-of-function experiments to inquire into the biological function of circKIF4A in the progression of glioma. We discovered that knockdown of circKIF4A remarkably decreased the proliferation and invasion ability of glioma cells. Moreover, subcutaneous tumorigenesis model and intracranial injection of orthotopic glioma model were established to investigate the functions of circKIF4A in vivo. Suppression of circKIF4A remarkably enhanced the sensitivity of glioma to temozolomide treatment. The glycolysis rate was accelerated by circKIF4A overexpression, which promoted glioma growth and temozolomide resistance. The glycolysis regulating enzyme ALDOA was regulated by circKIF4A through the mechanism of interactivity with miR-335-5p in glioma cells. In a word, our data showed that the upregulation of circKIF4A facilitates glioma progression by means of binding miR-335-5p and upregulating ALDOA expression.

Indexed as

Brain NeoplasmsGliomaRNA, CircularCell Line, TumorCell MovementCell ProliferationDrug Resistance, NeoplasmFructose-Bisphosphate AldolaseGene Expression Regulation, NeoplasticGlycolysisHumansKinesinsMicroRNAsTemozolomideALDOA protein, humanFructose-Bisphosphate AldolaseKIF4A protein, humanKinesinsMicroRNAsMIRN335 microRNA, humanRNA, CircularTemozolomide

Identifiers

PMID36030248
PMCPMC9420136
OpenAlexW4293364348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.